Action MRNS MARINUS PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Marinus Pharmaceuticals, Inc.

Actions

MRNS

US56854Q2003

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 07/06/2024 		Varia. 5j. Varia. 1 janv.
1,52 USD +1,33 % Graphique intraday de Marinus Pharmaceuticals, Inc. +7,04 % -86,02 %
17/05 Mise à jour sectorielle : Les actions du secteur de la santé sont mitigées en fin d'après-midi MT
17/05 Mise à jour sectorielle : Soins de santé MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Marinus Pharmaceuticals Investor Notice: Robbins LLP Reminds Stockholders to Seek Representation in the MRNS Class Action
BU
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Marinus Pharmaceuticals, Inc. with Losses to Contact the Firm
BU
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
PR
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BU
Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Marinus Pharmaceuticals, Inc. Investors – MRNS
BU
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
AQ
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
BU
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
AQ
Marinus Pharmaceuticals: Q1 Earnings Snapshot
AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
BU
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
BU
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
BU
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review
AQ
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
BU
Marinus Pharmaceuticals: Q4 Earnings Snapshot
AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MRNS
  4. Actualités Marinus Pharmaceuticals, Inc.
  5. Communiqués